A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

NCT06372821 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease
Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)
Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)
Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)

Interventions

DRUG: NIO752
OTHER: Placebo

Sponsor

University College, London

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]